Huaxia Eye Hospital Group Co Ltd
SZSE:301267
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3), the stock would be worth ¥21.35 (17% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.5 | ¥18.19 |
0%
|
| 3-Year Average | 3 | ¥21.35 |
+17%
|
| 5-Year Average | 3.1 | ¥22.06 |
+21%
|
| Industry Average | 2.3 | ¥16.2 |
-11%
|
| Country Average | 2.4 | ¥17.49 |
-4%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
|
15.3B CNY | 2.5 | 34.6 | |
| US |
|
HCA Healthcare Inc
NYSE:HCA
|
97.2B USD | -15.4 | 14.3 | |
| SA |
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
98B SAR | 12.4 | 40.8 | |
| ZA |
N
|
Netcare Ltd
JSE:NTC
|
23.2B ZAR | 2.1 | 13.8 | |
| MY |
I
|
IHH Healthcare Bhd
KLSE:IHH
|
77.8B MYR | 2.6 | 37.1 | |
| ZA |
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
17.5B ZAR | 1.5 | 4.5 | |
| BR |
|
Rede D'Or Sao Luiz SA
BOVESPA:RDOR3
|
84.8B BRL | 4.3 | 17.9 | |
| US |
|
Tenet Healthcare Corp
NYSE:THC
|
15.7B USD | 3.7 | 11.2 | |
| CN |
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
103.3B CNY | 4.6 | 30.3 | |
| IN |
|
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
|
1.1T INR | 12.2 | 61.3 | |
| US |
|
Ensign Group Inc
NASDAQ:ENSG
|
10.8B USD | 4.8 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Huaxia Eye Hospital Group Co Ltd
Glance View
Huaxia Eye Hospital Group Co Ltd has positioned itself as a key player in China’s healthcare landscape, specializing in comprehensive ophthalmic services. Emerging from the early stirrings of China's reforms in the healthcare sector, Huaxia capitalized on a burgeoning demand for specialized medical care. With roots tracing back to when accessible eye care was a luxury in China, Huaxia recognized the immense potential in providing quality eye treatments. As the country urbanized rapidly, vision ailments became increasingly prevalent, creating a vast market for ocular health services. Huaxia seized this opportunity by establishing a network of state-of-the-art facilities across major cities, providing services ranging from basic eye examinations to complex surgeries. The company's revenue model is built on a multifaceted approach, combining patient volume with specialized treatments. Catering to a diverse demographic, Huaxia offers tiered service options that suit various financial capacities, ensuring a steady stream of income. Beyond individual consultations, the company has fostered partnerships with corporations and insurance providers, further securing a stable client base. Moreover, Huaxia invests significantly in pioneering medical technology and staff training, enhancing its reputation and thereby drawing more patients seeking top-notch care. Through strategic expansion and consistently leveraging advancements in ophthalmology, Huaxia Eye Hospital Group Co Ltd has solidified its place not just as a healthcare provider, but as a critical architect shaping the future of eye care in China.